 |
|
© Medicine
Virginia / YouTube
|
An
artificial pancreas may soon be as close as your smartphone, as researches
prepare to begin final clinical tests for a device that would ease the burden
of type 1 diabetes.
The
device one can automatically measure sugar levels and support insulin delivery.
After
183,708 hours of clinical trials since 2008 and 20 years of research, the
University of Virginia School of Medicine is bringing its brainchild to nine
locations across the US and Europe to try it on 240 patients.
The
device’s name, “InControl,” means exactly that: it can control everything
people with diabetes need and – at least currently – have to do manually.
A
typical diabetes routine requires people to remember to check their
blood-glucose levels several times a day, and manually inject insulin.
This
smartphone-based “artificial pancreas” will automatically control sugar levels
every five minutes and report results to the app. It will analyze the data and
if, needed, adjust insulin levels via a small, wearable insulin pump. The app’s
algorithm is linked wirelessly to both the blood-sugar monitor and the pump, as
well as a remote-monitoring site.
"It
runs on a five-minute cycle and takes information from these devices and
calculates the next best option for the patient pretty much any point in time,”
said Chad Rogers, the CEO of TypeZero Technologies, which has licensed and
refined the technology.
The
whole system is also very discreet. The monitor is as tiny as a flash drive and
can be worn anywhere on the body. The pump, equipped with a needle as thin as a
bee-stinger, can be hooked anywhere on an individual’s clothes and will deliver
insulin to the patient’s blood stream when necessary.
“If
it’s working, you don’t know that it’s there,” Francis Doyle III, dean of
Harvard’s Paulson School of Engineering and Applied Sciences, told ArsTechnica.
The
final clinical tests of InControl are expected to start early this year.
“To
be ultimately successful as an optimal treatment for diabetes, the artificial
pancreas needs to prove its safety and efficacy in long-term pivotal trials in
the patient’s natural environment,” Dr. Boris Kovatchev, PhD, who leads the
research, said. “Our foremost goal is to establish a new diabetes treatment
paradigm: the artificial pancreas is not a single-function device; it is an
adaptable, wearable network surrounding the patient in a digital treatment
ecosystem.”
The
trial process will consist of two phases. The first six-month part will focus
on safety and effectiveness of the artificial pancreas. The 240 patients will
use the device and app in their daily routines, comparing the artificial
pancreas with a standard insulin pump.
The
second phase, also half-a-year long, will involve 180 of the 240 patients, who
will test the Harvard University-developed algorithm. This will help
researchers see if it needs to be perfected.
However, interested
diabetics shouldn’t hold their breath just yet. The researchers hope to have
the trials complete in four years, according to ARS.
Originally published in RT USA
No comments:
Post a Comment